Roche cuts PhII eye disease program, one day after another biotech flopped in same indication
Right after NGM failed to meet the primary endpoint in a Phase II eye disease trial, one of the Big Pharmas decided to remove a mid-stage candidate from its pipeline.
The update was quiet, announced in Roche’s Q3 earnings presentation, where the Swiss pharma said it was removing HtrA1 inhibitor galegenimab from its pipeline. Roche did not bring up the development in its earnings call Tuesday morning. However, a Roche spokesperson told Endpoints News Tuesday morning via email simply that:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.